CSL 324

Drug Profile

CSL 324

Alternative Names: Anti-CSF3 Therapeutic Antibody; Anti-G-CSFR mAb; CSL324; CSL324 G-CSFR; G-CSF antagonists - CSL

Latest Information Update: 18 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MuriGen Therapeutics; Zenyth Therapeutics
  • Developer CSL
  • Class Monoclonal antibodies
  • Mechanism of Action Granulocyte colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation; Rheumatoid arthritis

Most Recent Events

  • 30 Jun 2016 Phase-I clinical trials in Inflammation (In volunteers) in Australia (IV) (ACTRN12616000846426)
  • 30 Jun 2016 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in Australia (IV) (ACTRN12616000846426)
  • 21 Feb 2006 Preclinical trials in Inflammation in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top